Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2025-09-02 Declaration of Voting R…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a regulatory disclosure titled 'Number of Shares and Voting Rights' issued by Innate Pharma. It explicitly cites Article L. 233-8 II of the French Code de Commerce and Article 223-16 of the AMF General Regulation, which mandate the periodic disclosure of total shares and voting rights. This type of filing is a standard regulatory requirement for listed companies in France to keep the market informed of their capital structure. It does not fit into categories like 'Major Shareholding Notification' (which concerns specific investors) or 'Share Issue' (which concerns changes in capital), but rather serves as a general regulatory update on share counts. Therefore, it is classified as a Regulatory Filing (RNS).
2025-09-02 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement by Innate Pharma regarding the total number of shares and voting rights as of September 1, 2025, in compliance with French regulatory requirements (Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation). This type of disclosure is a standard regulatory filing for publicly traded companies in France to inform the market of changes in capital structure. It does not fit into specific categories like 'Share Issue' (as it is a status update, not an announcement of a new issuance) or 'Major Shareholding' (as it is not a notification of a threshold crossing by a shareholder). Therefore, it is classified as a Regulatory Filing (RNS).
2025-09-02 French
6-K
Foreign Filer Report
2025-08-04 English
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory announcement from Innate Pharma disclosing the total number of shares and voting rights as of August 1, 2025. This is a standard monthly regulatory requirement in France (AMF regulations) for listed companies to provide transparency regarding their capital structure. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' and is not a report publication announcement, but rather a mandatory regulatory disclosure of share capital data. Therefore, it is classified as a Regulatory Filing (RNS).
2025-08-04 French
Inside Information / Other news releases
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement by Innate Pharma regarding the total number of shares and voting rights as of a specific date (August 1, 2025). This is a standard regulatory disclosure required under French law (Code de Commerce and AMF General Regulation) for publicly traded companies to inform the market about share capital changes and voting rights. It does not fit into specific categories like 'Major Shareholding Notification' (which tracks external investors) or 'Share Issue' (which describes the act of issuance). Given it is a mandatory regulatory disclosure of share/voting data, it falls under the 'Regulatory Filings' (RNS) category.
2025-08-04 English
6-K
Foreign Filer Report
2025-07-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.